7-10 December 2019
ASH Annual Meeting & Exposition
Orlando, FL, USA
About Karus
We are a clinical-stage biopharmaceutical company, developing precision medicines for cancer.
Our Portfolio
Our two clinical candidates are in Phase I studies with the ambition to progress them into Phase II in 2019. Our preclinical research program includes a focus on a new generation of brain-penetrant, non-genotoxic small molecules under exploration in cancer, with potential in other indications.
Partner With Us
We wish to establish strategic collaborations with leading biopharmaceutical partners who are commercializing innovative anti-cancer therapeutics.
Karus Therapeutics is a clinical-stage biopharmaceutical company. We are developing precision medicines for cancer. Our orally-active, small molecule clinical candidates combine the effectiveness of targeted cancer cell activity and immunotherapy.
Karus featured in the Biology Impacting Lives programme from ITN Productions in partnership with the Royal Society of Biology.
Created by Instinctif Partners